Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proof-of-concept study of QGE031 in moderate to severe atopic dermatitis
2011-002112-84Phase 2Completed
- Sponsor
- Novartis
- Start
- Oct 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ligelizumab in atopic dermatitis (AD) (3 arms), sponsored by Novartis. Primary endpoint: Change in Eczema Area and Severity Index (EASI). Started Oct 2011; status: completed.
02
Drugs
ligelizumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2011-002112-84.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002112-84.